Kimberly-Clark To Acquire Kenvue In $48.7 Billion Deal
By Amit Chowdhry ● Yesterday at 9:30 AM
Kimberly-Clark announced plans to acquire Kenvue in a cash and stock transaction valuing the consumer health company at an enterprise value of approximately $48.7 billion. The deal, unanimously approved by both boards, will create a combined global leader with roughly $32 billion in annual net revenues and $7 billion in adjusted EBITDA. The transaction, based on the closing price of Kimberly-Clark stock on October 31, 2025, represents an acquisition multiple of about 14.3x Kenvue’s last twelve months adjusted EBITDA, or 8.8x when including expected run-rate savings of $2.1 billion. Kenvue is known for brands like Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, Zyrtec, Imodium, and Nicorette. And Kimberly-Clark is known for Huggies, Pull-Ups, Kleenex, Scott, Cottonelle, Depend, Kimwipes, and Safeskin.